GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating restated by equities researchers at J P Morgan Chase & Co in a research report issued on Wednesday.

A number of other research analysts have also issued reports on GSK. Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, Argus reiterated a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $44.67.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 40.83 on Wednesday. The firm has a market capitalization of $99.79 billion, a P/E ratio of 39.56 and a beta of 1.03. The firm’s 50-day moving average price is $40.35 and its 200 day moving average price is $41.57. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. Analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

WARNING: “GlaxoSmithKline PLC (GSK) Earns “Neutral” Rating from J P Morgan Chase & Co” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/18/glaxosmithkline-plc-gsk-earns-neutral-rating-from-j-p-morgan-chase-co.html.

Several hedge funds have recently added to or reduced their stakes in the company. Bonness Enterprises Inc. grew its position in shares of GlaxoSmithKline PLC by 75.2% in the third quarter. Bonness Enterprises Inc. now owns 41,700 shares of the pharmaceutical company’s stock valued at $1,693,000 after purchasing an additional 17,900 shares during the last quarter. Fulton Bank N.A. grew its position in shares of GlaxoSmithKline PLC by 4.9% in the third quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock valued at $3,056,000 after purchasing an additional 3,515 shares during the last quarter. Bogart Wealth LLC lifted its stake in shares of GlaxoSmithKline PLC by 40.6% during the second quarter. Bogart Wealth LLC now owns 35,816 shares of the pharmaceutical company’s stock valued at $1,544,000 after buying an additional 10,338 shares during the period. Intl Fcstone Inc. lifted its stake in shares of GlaxoSmithKline PLC by 151.2% during the second quarter. Intl Fcstone Inc. now owns 38,057 shares of the pharmaceutical company’s stock valued at $1,641,000 after buying an additional 22,909 shares during the period. Finally, Farmers National Bank lifted its stake in shares of GlaxoSmithKline PLC by 23.6% during the second quarter. Farmers National Bank now owns 18,446 shares of the pharmaceutical company’s stock valued at $795,000 after buying an additional 3,521 shares during the period. Institutional investors and hedge funds own 9.28% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.